LIDAMYCIN

作品数：19被引量：65H指数：6
导出分析报告
相关领域：医药卫生更多>>
相关作者：刘芳陈淑珍商悦甄永苏吴淑英更多>>
相关机构：中国医学科学院北京协和医学院中国医学科学院中国协和医科大学清华大学更多>>
相关期刊：《Science Bulletin》《中国抗生素杂志》《Science China(Life Sciences)》《Acta Pharmacologica Sinica》更多>>
相关基金：国家高技术研究发展计划国家自然科学基金国家重点基础研究发展计划更多>>
-
在结果中检索

检索结果分析

结果分析中...
共 条 记 录，以下是1-10
全选清除导出
参考文献引证文献引用追踪
视图：
排序：
Site-specific PEGylation of lidamycin and its antitumor activity被引量：2
《Acta Pharmaceutica Sinica B》2015年第3期264-269,共6页Liang Li Boyang Shang Lei Hu Rongguang Shao Yongsu Zhen 
supported by the National Science and Technology Major Project for Major New Drug Innovation (Nos.2013ZX09102064 and 2014ZX09201042-003)
In this study,N-terminal site-specific mono-PEGylation of the recombinant lidamycin apoprotein(r LDP) of lidamycin(LDM) was prepared using a polyethyleneglycol(PEG) derivative(Mw20 k Da) through a reactive terminal al...
关键词：Enediyne antibiotic Polyethylene glycol Site-specific PEGylation LIDAMYCIN 
Chloroquine potentiates the anti-cancer effect of lidamycin on non-small cell lung cancer cells in vitro被引量：4
《Acta Pharmacologica Sinica》2014年第5期645-652,共8页Fang LIU Yue SHANG Shu-zhen CHEN 
This investigation received support from the National Natural Science foundation of China （No 81072664 and 81373437） and the National Science and Technology Major Project of China （Grant No 2012ZX09301002-001-022-01）.Shu-zhen CHEN designed the study and edited the paper; Fang LIU performed the research, analyzed the data and wrote the paper; and Yue SHANG performed the mouse experiments.
Aim： To assess the synergistic actions of lidamycin （LDM） and chloroquine （CQ）, a lysosomal enzyme inhibitor, in human non-small cell lung cancer （NSCLC） cells, and to elucidate the potential mechanisms. Method...
关键词：lung cancer anticancer drug LIDAMYCIN CHLOROQUINE drug interaction synergism APOPTOSIS AUTOPHAGY 
Lidamycin inhibits tumor growth and pulmonary metastasis in murine breast carcinoma and shows synergy with paclitaxel
《Chinese Science Bulletin》2013年第23期2805-2811,共7页HU Lei ZHANG ShengHua SHAO RongGuang ZHEN YongSu 
supported by the Significant New Drugs Development Science and Technology Major Projects of China(2010ZX09401-407);State-level Public Welfare Scientific Research Institutes for Basic R&D Special Fund(IMBF201101)
The main goal of this study was to investigate whether lidamycin (LDM) could enhance the efficacy of paclitaxel (TAX) against breast cancer. In the MTT assay, LDM showed much more potent cytotoxicity than paclitaxel, ...
关键词：血管内皮生长因子 乳腺癌细胞 协同作用 力达霉素 紫杉醇 抑制肿瘤 肺 小鼠 
Optimization of the Assembly Efficiency for Lidamycin Chromophore Bound to its Apoprotein:A Case Study using Orthogonal Array被引量：9
《Biomedical and Environmental Sciences》2011年第6期602-607,共6页ZHONG Gen Shen GUO Xiao Fang ZHANG Sheng Hua ZHEN Yong Su 
supported by grants from "Significant new drug development" Science and Technology Major Projects of China (2009ZX09301-003; 2009ZX09401-005; 2010ZX09401-407)
Objective Lidamycin （LDM） can be dissociated to an apoprotein （LDP） and an active enediyne chromophore （AE）. The detached AE can reassemble with its LDP-containing fusion protein to endow the latter with potent ...
关键词：LIDAMYCIN CHROMOPHORE HPLC Orthogonal array Assembly rate Lidamycin CHROMOPHORE HPLC Orthogonal array Assembly rate 
Antitumor effects of an engineered and energized fusion protein consisting of an anti-CD20 scFv fragment and lidamycin被引量：6
《Science China(Life Sciences)》2011年第3期255-262,共8页FANG Hong MIAO QingFang ZHANG ShengHua CHENG Xin XIONG DongSheng ZHEN YongSu 
supported by the National High Technology Research and Development Program of China(Grant No. 2006AA02A255);the National Natural Science Foundation of China(Grant No. 30701029);the National Science and Technology Major Projects(Grant Nos.2009ZX09103-720 and 2010ZX09401-407)
Antibody-based fusion proteins are the next generation of antibody therapies for cancer and other diseases.CD20 antigen,which is overexpressed on cell membranes in nearly 95% of cases of B-cell Non-Hodgkin's Lymphoma,...
关键词：LYMPHOMA CD20 LIDAMYCIN SCFV energized fusion protein 
Lidamycin Induces Apoptosis of B-Cell Lymphoma Cells and Inhibits Xenograft Growth in Nude Mice
《Clinical oncology and cancer researeh》2009年第3期203-207,共5页Hong Fang Shenghua Zhang Qingfang Miao Dongsheng Xiong Yongsu Zhen 
supported by a grant from the National High Technology Research and Development Program of China(No.2006AA02A255).
OBJECTIVE To study the cytotoxicity of Lidamycin （LDM） and its induction of apoptosis in Raji and Daudi cells of B-cell lymphoma, and the inhibition of growth of the lymphoma Raji xenograft in nude mice. METHODS MTT...
关键词：lidamycin （LDM） LYMPHOMA B-CELL apoptosis. 
Lidamycin shows highly potent cytotoxic to myeloma cells and inhibits tumor growth in mice被引量：8
《Acta Pharmacologica Sinica》2009年第7期1025-1032,共8页Yong-zhan ZHEN Ya-jun LIN Yi LI Yong-su ZHEN 
Aim： To investigate the effects of lidamycin （LDM） on a mouse myeloma cell line （SP2/0） and human multiple myeloma cell lines （U266 and SKO-007）, and provide the basis for the use of LDM in cancer therapy. Meth...
关键词：LIDAMYCIN mouse myeloma multiple myeloma JNK SP2/0 cells 
Role of Prosurvival Molecules in the Action of Lidamycin toward Human Tumor Cells
《Biomedical and Environmental Sciences》2009年第3期244-252,共9页A-JING YANG WEI-WEI SHI YONG LI ZHEN WANG RONG-GUANG SHAO DIAN-DONG LI QI-YANG HE 
supported by grants from the National Natural Science Foundation of China (No. 30672482);the National 973 Program (No. 2009CB521807)
Objective Lidamycin, an enediyne antibiotic, leads to apoptosis and mitotic cell death of human tumor cells at high and low concentrations. The reason why tumor cells have distinct responses to lidamycin remains elusi...
关键词：LIDAMYCIN Prosurvival molecules SIRTI deacetylase Apoptosis Mitotic cell death Multidrug resistance 
Synergy of gemcitabine and lidamycin associated with NF-κB downregulation in pancreatic carcinoma cells被引量：4
《Acta Pharmacologica Sinica》2008年第5期614-619,共6页Jing CHEN Shu-ying WU Zhi-gang OU-YANG Yong-su ZHEN 
This work was supported by The National High Technology Research and Development Program of China （No 2004AA2Z3950） and a grant from the National Natural Science Foundation of China （No 30400597）.
Aim： To investigate the effects on human pancreatic cancer PANC- 1 and SW1990 cells using a combination of lidamycin （LDM） and gemcitabine. Methods： A 3- （4,5-dimethylthiazol-2-yl）-2,5-diphenyltetrazolium bromid...
关键词：LIDAMYCIN GEMCITABINE pancreatic cancer K-RAS NF-ΚB drug therapy  combination 
Generation and antitumor effects of an engineered and energized fusion protein VL-LDP-AE composed of single-domain antibody and lidamycin被引量：3
《Science China(Life Sciences)》2007年第4期447-456,共10页MIAO QingFang, SHANG BoYang, OUYANG ZhiGang, LIU XiaoYun & ZHEN YongSu Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100050, China 
Supported by the National High Technology Research and Development Program of China (863 Program)(Grant No. 2006AA02A255)
Type IV collagenase plays a pivotal role in invasion, metastasis and angiogenesis of tumor. Single domain antibodies are attractive as tumor-targeting vehicle because of their much smaller size com-pared with antibody...
关键词：type IV COLLAGENASE SINGLE-DOMAIN ANTIBODY LIDAMYCIN fusion protein antibody-based drugs 
全选清除导出
共2页<12>
检索报告 对象比较 聚类工具 使用帮助 返回顶部